ASCO GU 2023-Bladder Cancer
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
Daniel P. Petrylak, MD, overviews the TROPHY-U-01 study for platinum-ineligible patients with metastatic UC.
Christine Ibilibor, MD, shares the race disparities in UC diagnoses and outcomes, as well as strategies to mitigate them.
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
A study presented at the 2023 ASCO GU Cancers Symposium evaluated K17 expression in several forms of urothelial carcinoma.
A research team sought to define the tumor protein co-expression of PD-L1, c-MET, and HER2 in a cohort of patients with mUC.
IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy.
Researchers analyzed the impact of EV+P or EV alone on QOL and symptoms based on the EV-103 Cohort K trial.
A recent study analyzed the effectiveness of BCG treatment in patients with NMIBC, including a subgroup of patients with CIS.
Long-term follow-up from the JAVELIN Bladder 100 trial examined the drug’s effect on OS from the start of 1L chemotherapy.
Dr. Aragon-Ching highlights the clinical trials being presented at the ASCO GU symposium for metastatic UC.
Norman E Sharpless, MD, University of North Carolina School of Medicine, will present the keynote session.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.